Stock Events

Moderna 

€55.44
2013
-€0.57-1.02% Friday 15:35

Statistics

Day High
57.72
Day Low
55.52
52W High
157.28
52W Low
55.52
Volume
3,109
Avg. Volume
2,099
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

31OctExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-8.98
-5.82
-2.65
0.51
Expected EPS
-1.47870053778
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1MRNA.MI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap164.39B
Pfizer is a direct competitor in the COVID-19 vaccine market, with its mRNA vaccine developed in collaboration with BioNTech.
BioNTech
BNTX
Mkt Cap20.98B
BioNTech SE partnered with Pfizer to develop a COVID-19 mRNA vaccine, competing directly with Moderna's mRNA vaccine.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson competes in the COVID-19 vaccine space with its viral vector vaccine, offering an alternative to mRNA vaccines.
Astrazeneca
AZN
Mkt Cap271.67B
AstraZeneca competes with Moderna with its COVID-19 vaccine developed in collaboration with Oxford University, using a different technology (viral vector).
Novavax
NVAX
Mkt Cap1.98B
Novavax offers a protein subunit COVID-19 vaccine, providing an alternative to Moderna's mRNA vaccine.
Sanofi
SNY
Mkt Cap141.43B
Sanofi, through its partnership with GlaxoSmithKline, is developing COVID-19 vaccines that compete with Moderna's offerings.
GSK
GSK
Mkt Cap89.55B
GlaxoSmithKline, in collaboration with Sanofi, is working on COVID-19 vaccines, positioning it as a competitor to Moderna.
CureVac N.V.
CVAC
Mkt Cap704.35M
CureVac competes in the mRNA space, focusing on developing mRNA-based vaccines and therapeutics, including for COVID-19.
Merck
MRK
Mkt Cap300.25B
Merck is involved in the development of COVID-19 treatments and vaccines, making it a competitor in the broader infectious disease market.
Abbott Laboratories
ABT
Mkt Cap197.08B
Abbott Laboratories competes with Moderna in the broader healthcare sector, including diagnostics and medical devices for infectious diseases.

About

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Mr. Stephane Bancel
Employees
5600
Country
US
ISIN
US60770K1079

Listings